Endoscopic therapy for gastric stromal tumors originating from the muscularis propria

Liu-Ye Huang, Jun Cui, Yun-Xiang Liu, Cheng-Rong Wu, De-Liang Yi

Liu-Ye Huang, Jun Cui, Yun-Xiang Liu, Cheng-Rong Wu, De-Liang Yi, Department of Gastroenterology, Yantai Yu Huang Ding Hospital, Yantai 264000, Shandong Province, China

Author contributions: Huang LY, Cui J and Liu YX designed and initiated the study; Wu CR and Yi DL performed a literature search; Additional cross searching was performed by Cui J; Huang LY drafted and wrote the paper; Cui J critically revised the paper.

Correspondence to: Dr. Jun Cui, Department of Gastroenterology, Yantai Yu Huang Ding Hospital, Yantai 264000, Shandong Province, China. cuijun89@163.com

Telephone: +86-535-6691999 Fax: +86-535-6240341
Received: November 22, 2011 Revised: March 23, 2012
Accepted: March 29, 2012
Published online: July 14, 2012

Abstract

AIM: To explore endoscopic therapy methods for gastric stromal tumors originating from the muscularis propria.

METHODS: For 69 cases diagnosed as gastric stromal tumors originating from the muscularis propria, three types of endoscopic therapy were selected, based on the size of the tumor. These methods included endoscopic ligation and resection (ELR), endoscopic submucosal excavation (ESE) and endoscopic full-thickness resection (EFR). The wound surface and the perforation of the gastric wall were closed with metal clips. Immunohistostaining for CD34, CD117, Dog-1, S-100 and smooth muscle actin (SMA) was performed on the resected tumors.

RESULTS: A total of 38 cases in which the tumor size was less than 1.2 cm were treated with ELR; three cases were complicated by artificial perforation, and all of the perforations were closed with metal clips. All of the 69 cases recovered with medical treatment, and none required surgical operation. Immunohistostaining demonstrated that among all of the 69 gastric stromal tumors diagnosed by gastroscopy, 12 cases were gastric leiomyomas (SMA-positive), and the other 57 cases were gastric stromal tumors.

CONCLUSION: Gastric stromal tumors originating from the muscularis propria can be treated successfully with endoscopic techniques, which could replace certain surgical operations and should be considered for further application.

INTRODUCTION

Gastric stromal tumors are the most common mesenchymal tissue-originated tumors in the digestive tract; these tumors are often found at the gastric fundus, the front wall of the gastric corpus and the antrum and can be sorted based on tissue of origin as originating from the muscularis mucosa or the muscularis propria. As the location of the tumors originating from the muscularis mucosa.
mucosae is superficial, endoscopic resection or ligation was has been widely performed to treat these tumors. In contrast, the location of the tumors originating from the muscularis propria is deep, especially when the tumors grow outside the gastric wall, so perforation often occurs during endoscopic therapy and the tumor cannot be resected easily and thoroughly. Therefore, this tissue of origin has often been considered to be a contraindication for endoscopic therapy, and the traditional treatment for such tumors is a surgical or laparoscopic operation\cite{1-5}.

In recent years, on the basis of sufficient clinical practice, we treated gastric stromal tumors originating from the muscularis propria with endoscopic techniques and obtained satisfactory therapeutic effects, which are reported as follows.

**MATERIALS AND METHODS**

**Patients**

A total of 69 patients (36 males and 33 females, age range 24-68 years, mean age 42.5 years) were diagnosed with gastric stromal tumors originating from the muscularis propria by gastroscopy and endoscopic ultrasonography from January 2008 to March 2011. Among the 69 cases, 19 tumors were located at the gastric antrum, 24 tumors were located at the gastric corpus, and 26 tumors were located at the gastric fundus. Each patient exhibited only one tumor, and no metastasis was detected via computed tomography (CT) examination. Routine blood tests, tests of blood coagulation function and hepatic and renal function, electrocardiograms and abdominal CTs were performed before the endoscopic therapy, and each patient’s written informed consent was obtained.

**Instruments**

The following instruments were used: Electronic gastroscope (Olympus GIF-Q260J, Olympus company, Japan), hyaline cap (D-201-11304, Olympus company, Japan), spiculiform cutting knife (KD-1 L-1, Olympus company, Japan), IT knife (KD-611 L, Olympus company, Japan), hook knife (KD-620 LR, Olympus company, Japan), injection needle (NM-200 L-0525, Olympus company, Japan), snare (AS-1-S, ASJ-1-S, COOK company, United States), hot biopsy forceps (FD-410 LR, Olympus company, Japan), hemostatic clip (HX-610-90, Olympus company, Japan; HX-600-135, Olympus company, Japan; Boston Resolution™, Boston company, United States), high frequency electric knife (ERBE VIO 200S, ERBE company, Germany), and Argon Plasma Coagulation instrument (ERBE APC®, ERBE company, Germany).

**Endoscopic therapeutic methods**

**Endoscopic ligation and resection**: Endoscopic ligation and resection (ELR) was used for gastric stromal tumors of which the size was less than 1.2 cm. A COOK ligator was assembled on the tip of the gastroscope, and the gastroscope was inserted into the stomach. The ligator was aimed at the tumor, and sufficient aspiration was applied to the tumor that the whole tumor entered the ligator, at which time the rubber band on the ligator was released to ligate the tumor. The purpose of the ligation was to manipulate the gastric stromal tumor into the shape of a polypoid, after which a snare was used to hitch the tumor, and it was resected. The resected tumor was removed for pathologic diagnosis, and the stump was closed with metal clips. If the procedure was complicated by perforation, the perforation was generally small and could be closed with metal clips (Figure 1).

**Endoscopic submucosal excavation**: Endoscopic submucosal excavation (ESE) was performed for gastric stromal tumors originating from the muscularis propria by the following steps. (1) Marking: Argon plasma coagulation (APC) was used to mark the border of the gastric stromal tumor; (2) Submucosal injection: A mixture of indocarminum, adrenalin and physiological saline (2-3 mL of indocarminum, 1 mL of adrenalin and 100 mL of physiological saline) was injected at the lateral of the mark; (3) Dissection: the mucosa was dissected with a needle knife; (4) Excavation: the submucosa was dissected with a needle knife; when the tumor was exposed, dissection was performed around the margin of the tumor, and when the dissection was finished, the tumor could be resected wholly with a snare; and (5) Wound surface handling: for small vessels bleeding on the surface, hot biopsy forceps or APC could be used for hemostasis, and if necessary, metal clips could be used (Figure 2).

**Endoscopic full-thickness resection**: A hyaline cap was assembled on the tip of the gastroscope before the endoscopic full-thickness resection (EFR) procedure, and intravenous anesthesia was performed using propofol for patients. EFR was then performed using the following steps. (1) Pre-cutting the mucosa and submucosa around the gastric stromal tumor: APC was used to mark the margin of the tumor; a mixture of indocarminum, adrenalin and physiological saline (2-3 mL of indocarminum, 1 mL of adrenalin and 100 mL of physiological saline) was injected at the lateral portion of the mark, using approximately 2-3 mL of the mixture for each injected point; the mucosa and submucosa around the gastric stromal tumor were pre-cut with a hook knife, and thus the tumor was exposed; (2) Dissection of the muscularis propria around the gastric stromal tumor: a hook knife or IT knife was used to dissect the tumor from the muscularis propria to the serous membrane; (3) Dissection of the serous membrane around the tumor: typically, the tumor was in compact adhesion with the serous membrane; thus the tumor could not be directly dissected with an IT knife, so instead, the serous membrane was cut around the tumor with a needle knife or hook knife, and an “artificial” perforation was made; (4) Full resection of the tumor: the liquid in the stomach was aspirated completely, and an IT knife or hook knife was used to cut the serous membrane around the tumor, after which the tumor was completely resected; and (5)
Figure 1  Endoscopic ligation and resection treatment for a gastric stromal tumor less than 1.2 cm in size originating from the muscularis propria. A: Submucosa lesion at the posterior wall of the gastric corpus; B: Endoscopic ultrasound shows that the lesion originates from the muscularis propria; C: COOK ligator aimed at the lesion, ready to ligate; D: The ligated stromal tumor was in the shape of a polypoid with deuto-stem; E: A snare was used to cut the tumor above the rubber band; F: The wound surface was closed with metal clips.

Figure 2  Endoscopic submucosal excavation treatment for a gastric stromal tumor originating from the muscularis propria that is larger than 1.2 cm. A: Submucosa lesion at the gastric corpus; B: Endoscopic ultrasound shows that the lesion originates from the muscularis propria; C: The mucosa of the stromal tumor was cut after submucosal injection; D: Dissection with an IT knife; E: The excavated wound surface, showing that no perforation occurred; F: The resected stromal tumor (4 cm in size).
Closure of the wound surface of the stomach: a metal clip was used to close the wound surface from the rim to the center. If the wound surface defect was too large to be closed with a metal clip directly, negative pressure aspiration was used to aspirate the omentum majus into the stomach, and then a metal clip was used to close the wound surface defect (Figure 3).

**Specimen handling**

The resected specimens were fixed in neutral formalin for pathologic diagnosis. Immunohistostaining of CD34, CD117, Dog-1, S-100 and smooth muscle actin (SMA) was performed for specimens suspected of being gastric stromal tumors[6-10].

**Postoperative handling**

For patients without perforation, the measures of fasting, infection prevention and limiting acid with proton pump inhibitors were sufficient. For patients with “artificial” perforation, if pneumoperitoneum was serious, evacuation was performed during and after the operation. The evacuating needle was inserted into the lower right quadrant to release abdominal distension. A semi-reclining position was recommended after the operation, along with the use of fasting and gastrointestinal decompression, to allow the perforation to heal. Abdominal pain, abdominal distension and signs of peritoneal irritation after the operation were carefully observed. Meglumine diatrizoate was recommended to be taken orally three days after the operation. To confirm whether there was extravasation of the contrast media and to observe stomach motivation, ultrasonic examination was conducted to observe whether there was hydrops in the abdominal cavity and pelvic cavity. Gastroscopy was...
performed one month after the operation to observe the conditions of the wound surface and whether there was residual or recurrence.

RESULTS

Effects of endoscopic therapy
ELR: Thirty-eight patients with gastric stromal tumors with a size of less than 1.2 cm underwent ELR, in which the tumor was ligated wholly and then resected. The procedure was complicated by perforations in 3 patients, and all of the wound surfaces and perforations were closed with metal clips. The patients recovered with medical treatment, and no patient needed surgical operation.

ESE: Eighteen patients with gastric stromal tumors in which the size of the specimen resected was more than 1.5 cm underwent ESE. The tumors were resected successfully, and no perforations complicated the procedure.

EFR: Thirteen patients with gastric stromal tumors, for which the size of the specimen resected was more than 2.0 cm, underwent EFR. The tumors were resected successfully, but “artificial” perforation occurred in all of the patients. All of the perforations were closed with metal clips, and meglumine diatrizoate upper gastroenterography three days after the operation showed that there was no extravasation of the contrast media. Gastroscopy showed that the wound surface of the stomach was nearly healed on the 9th day after the operation (Figure 3H).

Immunohistostaining
The positive expression rates of CD34, CD117, Dog-1, S-100 and SMA in the 69 patients who were diagnosed with gastric stromal tumors by gastroscopy were 81.2% (56/69), 82.6% (57/69), 82.6% (57/69), 0% and 17.4% (12/69), respectively, which demonstrated that, among the 69 patients, there were 12 leiomyomas, which express SMA; the other 57 patients had gastric stromal tumors.

Average stay
The average stay for all of the patients was 8.4 ± 2.4 d.

Residual or recurrence of the tumor
Gastroscopy and abdominal CT scans were performed one month after the operation; these procedures showed that the wound surfaces had healed, and there was no residual or recurrence.

DISCUSSION

Stromal tumor is the most common mesenchyme-originated tumor; as it has potential cancerous tendencies, gastric stromal tumor is recommended to be resected[11-15]. For gastric stromal tumors originating from the muscularis propria in which the size was less than 1.2 cm, ELR was the ideal method[14]. After ligation, each tumor was in the shape of a polyoid with a deuto-stem, which made snare resection easy; additionally, a pathologic diagnosis could be obtained with the resected tumor. Because the wound surface in the stomach was not large, perforation would not generally occur; however, if perforation did occur, it could be closed with metal clips. With the medical treatment of fasting, gastrointestinal decompression and proton pump inhibitors, the patients would recover. There were 38 patients in this study in whom the tumor size was less than 1.2 cm; these patients were treated with ELR. Moreover, 3 of these patients were complicated by perforation; the perforations were closed with metal clips, and no surgical assistance was required. Because the texture of the stromal tumor was hard, it could not be as easily aspirated as mucosa or vascular tissue, so the ligation for the stromal tumor required a long period of aspiration. According to our experience, when the stromal tumor was ligated, a red-colored sign occurred when the tumor was aspirated, and at least another one-minute maximum aspiration was necessary to ensure that the rubber band could fully hitch the tumor.

EFR is another effective measure for the treatment of tumors originating from the submucosa or muscularis propria. For tumors of 3.0 cm or less in size originating from the muscularis propria, the achievement ratio of ESE was high and the patient suffered less, whereas the complication rate was low. ESE was able to excavate the whole tumor successfully, and a pathologic diagnosis could be performed using the resected specimen, which was able to provide a systemic and safe therapeutic method for each patient. In this study, there were 18 patients with gastric stromal tumors originating from the muscularis propria who underwent ESE; all of the tumors were excavated wholly, and no perforations occurred.

For patients with gastric stromal tumors originating from the muscularis propria, the perforation rate of endoscopic therapy is high; therefore, the traditional treatment method is surgical operation or therapeutic laparoscopy, especially for stromal tumors larger than 2 cm[17-20]. A total of 13 patients in this study underwent EFR, and perforation occurred in all of the patients. The sizes of the 13 tumors were all larger than 2 cm, all of the perforations were closed with metal clips, the abdominal cavity pressure decreased with the use of abdominal paracentesis, all of the patients recovered with medical treatment, and no patients needed surgical help. The key point in avoiding complications was the use of endoscopic metal clips for oversewing: according to our experience, for larger perforations, the perforation should be closed with metal clips from rim to center, known as oversewing, and even some normal mucosa should be sewed up to decrease the perforation. The key point for successful EFR is to mend the perforation successfully, avoiding surgical mending and postoperative peritonitis[21,22]. The most widely used method to mend perforation is metal clip sutura[23,24]. For small perforations, one or several metal clips could overview the per-
A perforation can influence the field of vision in the stomach, making endoscopic operation difficult; thus, during EFR, repeated abdominal touch was necessary. If the pressure in the abdominal cavity increased, prompt evacuation was needed; the puncture site was in the right lower quadrant, and the needle was a commonly used 20 mL injection needle. After puncture, the abdomen was compressed to exhaust the air, the needle was detained until the perforation was closed and the pneumoperitoneum had clearly improved, and the needle was removed when it was confirmed that there was no further gas exhausting from the abdominal cavity.

It is difficult to distinguish gastric stromal tumors from leiomyomas and schwannomas based on cell shape. The clinical diagnosis of this tumor type mainly depends on histopathology, immunohistochemistry (CD34- and CD117-positive) and protocols in molecular biology. CD34 is the antigen marker of myeloid stem cells; it resides in the marrow hematopoietic stem cell tissue. CD117 is the product of the c-kit oncogene; it is the receptor of tyrosine kinase growth factor. The Dog-1 gene is located at chromosome 11q13; it has 26 exons and is 114 Kb in length; the protein has 8 trans-membrane functional areas; it may be a chloride channel regulated by calcium ions, and it is currently recognized as the most sensitive and specific marker for gastrointestinal stromal tumors (GIST). Typical leiomyomas and schwannomas do not express CD34; SMA-positive expression is the typical characteristic of leiomyoma, and S-100-positive expression is the typical characteristic of schwannomas. The positive expression rates of CD34, CD117, Dog-1, S-100 and SMA in the 69 patients were 81.2% (56/69), 82.6% (57/69), 82.6% (57/69), 0% and 17.4% (12/69), respectively, which demonstrated that, among the 69 patients, there were 12 leiomyomas, which express SMA, and the other 57 patients had gastric stromal tumors confirmed with immunohistochemistry. Currently, the main treatment method for GISTs is surgical operation; the majority of benign GISTs in this study had a good prognosis after resection, and there was no recurrence in a short time. GISTs are not sensitive to radiotherapy or chemotherapy. For malignant GISTs that could not be completely resected or with recurrence, patients could take imatinib for therapy. Imatinib is an inhibitor of tyrosine kinase; it has significant therapeutic effects on malignant GISTs that express CD117[33,35].

With the maturation of EFR, more and more gastric stromal tumors originating from the muscularis propria would avoid surgical operations, sharing the benefits provided by therapeutic endoscopy techniques.

**COMMENTS**

**Background**

The traditional method for the treatment of gastric stromal tumor originating from the muscularis propria was laparoscopic or surgical operation; in recent years, with the development of endoscopic techniques and instruments, endoscopic therapy for gastric stromal tumors originating from the muscularis propria has been made possible.

**Research frontiers**

Gastric stromal tumor is the most common mesenchymal tissue-originated tumor in the digestive tract; based on the tissue of origin, it can be defined as originating from the muscularis mucosae or the muscularis propria. As the location of the tumor originating from the muscularis mucosae was superficial, endoscopic resection or ligation was commonly performed. In contrast, the location of a tumor originating from the muscularis propria was deep, especially when the tumor grew outside gastric wall, perforation often occurred during endoscopic therapy, and the tumor could not be resected easily and thoroughly. Therefore, this tissue of origin was often considered to be a contraindication for endoscopic therapy, and the traditional treatment for such tumors was surgical or laparoscopic operation. In recent years, on the basis of sufficient clinical practice, endoscopic treatment for gastric stromal tumors originating from the muscularis propria has become possible.

**Innovations and breakthroughs**

Depending on the size of gastric stromal tumors originating from the muscularis propria, three types of endoscopic therapy could be used to treat the tumor. These techniques were endoscopic ligation and resection, endoscopic submucosal excavation and endoscopic full-thickness resection. The wound surface and the perforation of the gastric wall were closed with metal clips. These results showed that some gastric stromal tumor originating from muscularis propria can be treated successfully with endoscopic techniques, which could replace some surgical operations.

**Applications**

The study results suggest that some gastric stromal tumors originating from the muscularis propria could be treated successfully with endoscopic techniques, which could replace some surgical operations.

**Terminology**

Gastrointestinal stromal tumor (GIST): This term indicates a particular type of lesion intermedius-originating tumor in the gastrointestinal tract; usually CD117 was positively expressed. Histologically, this tumor type is often composed of spindle cells and epithelioid cells. With respect to immunophenotype, it expresses the c-kit protein, which is driven by mutated c-kit or platelet-derived growth factor receptors. It is recognized that GIST originate from the intestinal cells of Cajal in gastrointestinal tract, which are in the shape of a network structure distributed in the muscular layer of gastrointestinal tract; this network is the pacemaker of slow-wave activity in the gastrointestinal tract and participates in the mechanism of excitatory disease and tumor formation in the gastrointestinal tract.

**Peer review**

This is a good paper on endoscopic resection of gastric stromal tumors and leiomyomas. The figures are excellent.
REFERENCES

1 Bamboat ZM, Dematteo RP. Updates on the management of gastrointestinal stromal tumors. Surg Oncol Clin N Am 2012; 21: 361-376.

2 Orsenigo E, Gazzetta P, Palo SD, Tamburini A, Staudacher C. Experience on surgical treatment of gastrointestinal stromal tumor of the stomach. Updates Surg 2010; 62: 101-104.

3 Tanabe K, Urabe Y, Tomokuno N, Suzuki T, Yamamoto H, Oka S, Tanaka S, Ohdan H. A new method for intraluminal gastrointestinal stromal tumor resection using laparoscopic seromuscular dissection technique. Dig Surg 2010; 27: 461-465.

4 Meza JM, Wong SL. Surgical options for advanced/meta-static gastrointestinal stromal tumors. Curr Probl Cancer 2011; 35: 283-293.

5 Grover S, Ashley SW, Raut CP. Small intestine gastrointestinal stromal tumor stalks. Curr Opin Gastroenterol 2012; 28: 113-123.

6 Kang YN, Jung HR, Hwang I. Clinicopathological and immunohistochemical features of gastrointestinal stromal tumors. Cancer Res Treat 2010; 42: 135-143.

7 Novelli M, Rossi S, Rodriguez-Justo M, Taniere P, Seddon V, Hostein I, Neuville A, Wozniak A, Sciot R, Schöffski P, Liggero S. DOG1 and CD117 are the antibodies of choice in the diagnosis of gastrointestinal stromal tumors. Histopathology 2010; 57: 259-270.

8 Corless CL, Barnett CM, Heinrich MC. Gastrointestinal stromal tumours: origin and molecular oncology. Nat Rev Cancer 2011; 11: 865-878.

9 Rossi S, Gasparotto D, Toffolatti L, Pastrello C, Gallina G, Marzotto A, Sartor C, Barabesichi M, Cantaloni C, Messerini L, Bearzi I, Arrigoni G, Mazzoleni G, Fletcher JA, Casali FG, Talamin R, Maestri R, Den Back AP. Molecular and clinicopathologic characterization of gastrointestinal stromal tumors (GISTs) of small size. Am J Surg Pathol 2010; 34: 1480-1491.

10 Chugh R. Current directions in systemic therapy for gastrointestinal stromal tumors. Curr Probl Cancer 2011; 35: 255-270.

11 Mrowiec JS, Jablotska B, Liszka L, Papaj J, Leidgens M, Szypko R, Sandecka A, Lampe P. Prognostic factors for survival after post surgery for patients with gastrointestinal stromal tumors. Eur Surg Res 2012; 48: 5-9.

12 Lagarde P, Pérot G, Kauffmann A, Brulard C, Dapremont D, Hostein I, Neuville A, Wozniak A, Sciot R, Schöffski P, Aurias A, André JM, Debiec-Rychter M, Chlon B, Mitotic checkpoints and chromosome instability are strong predictors of clinical outcome in gastrointestinal stromal tumors. Clin Cancer Res 2012; 18: 826-838.

13 Goh BK, Chow PK, Chok AY, Chan WH, Chung YF, On HS, Wong WK. Impact of the introduction of laparoscopic wedge resection as a surgical option for suspected small/medium-sized gastrointestinal stromal tumors of the stomach on perioperative and oncologic outcomes. World J Surg 2010; 34: 1847-1852.

14 Sasaki A, Koeda K, Obuchi T, Nakajima J, Nishizuka S, Terashiba M, Wakaibayashi G. Tailored laparoscopic resection for suspected gastric gastrointestinal stromal tumors. Surgery 2010; 147: 516-520.

15 Caram MV, Schuetze SM. Advanced or metastatic gastrointestinal stromal tumors: systemic treatment options. J Surg Oncol 2011; 104: 888-895.

16 Huang WH, Feng CL, Lai HC, Yu CJ, Chou JW, Peng CY, Yang MD, Chiang IP. Endoscopic ligation and resection for the treatment of small EUS-suspected gastric GI stromal tumors. Gastrointest Endosc 2010; 71: 1076-1081.

17 Warzi AA, Peyser PM. Laparoscopic resection of gastric GIST and benign gastric tumours: evolution of a new technique. Surg Endosc 2010; 24: 72-78.

18 Frankel TL, Wong SL. Surgical management of gastrointestinal stromal tumors. Curr Probl Cancer 2011; 35: 271-282.

19 Sepe PS, Brugge WR. A guide for the diagnosis and management of gastrointestinal stromal cell tumors. Nat Rev Gastroenterol Hepatol 2009; 6: 363-371.

20 Grotz TE, Donohue JH. Surveillance strategies for gastrointestinal stromal tumors. J Surg Oncol 2011; 104: 921-927.

21 Ikeda K, Sumiyama K, Tajiri H, Yasuda K, Kitano S. Evaluation of a new multitasking platform for endoscopic full-thickness resection. Gastrointest Endosc 2011; 73: 117-122.

22 Wang L, Ren W, Fan CQ, Li YH, Zhang X, Yu J, Zhao GC, Zhao XY. Full-thickness endoscopic resection of noninfracavitary gastric stromal tumors: a novel approach. Surg Endosc 2011; 25: 641-647.

23 Agravat D, Chak A, Champagne BJ, Marks JM, Delaney CP. Endoscopic mucosal resection with full-thickness closure for difficult polyps: a prospective clinical trial. Gastrointest Endosc 2011; 71: 1082-1088.

24 Kopelman Y, Siersema PD, Nir Y, Szol A, Babaye A, Segol O, Willenz EP, Leluc S, Geller A, Kopelman D. Endoluminal compression clip: full-thickness resection of the mesenteric bowel wall in a porcine model. Gastrointest Endosc 2009; 70: 1146-1157.

25 Fritscher-Ravens A, Cuming T, Jacobsen B, Sehusen F, Ghanbri A, Kahl K, von Herbay A, Koehler P, Milla P. Feasibility and safety of endoscopic full-thickness esophageal wall resection and defect closure: a prospective long-term survival animal study. Gastrointest Endosc 2009; 69: 1314-1320.

26 Joensuu H, DeMatteo RP. The management of gastrointestinal stromal tumors: a model for targeted and multidisciplinary therapy of malignancy. Annu Rev Med 2012; 63: 247-258.

27 Abe N, Takeuchi H, Yanagida O, Masaki T, Mori T, Sugiyama M, Atomi Y. Endoscopic full-thickness resection with laparoscopic assistance as hybrid NOTES for gastric submucosal tumor. Surg Endosc 2009; 23: 1908-1913.

28 Vij M, Agraval V, Kumar A, Pandey R. Gastrointestinal stromal tumors: a clinicopathological and immunohistochemical study of 121 cases. Indian J Gastroenterol 2010; 29: 231-236.

29 Bennett JJ, Rubino MS. Gastrointestinal stromal tumors of the stomach. Surg Oncol Clin N Am 2012; 21: 21-33.

30 Wong NA, Shelley-Fraser G. Specificity of DOG1 (K9 clone) and protein kinase C theta (clone 27) as immunohistochemical markers of gastrointestinal stromal tumours. Histopathology 2010; 57: 250-258.

31 Yeh CH, Pan KT, Chu SY, Chen CM, Hsu MY, Hung CF, Tseng JH. Safety and efficacy of image-guided percutaneous biopsies in the diagnosis of gastrointestinal stromal tumors. Clin Imaging 2012; 36: 19-23.

32 Yoon HY, Kim CB, Lee YH, Kim HG. Gastric schwannoma. Yonsei Med J 2008; 49: 1052-1054.

33 Essat M, Cooper K. Imatinib as adjuvant therapy for gastrointestinal stromal tumors: a systematic review. Int J Cancer 2011; 128: 2202-2214.

34 Kim EJ, Zalupski MM. Systemic therapy for advanced gastrointestinal stromal tumors: beyond imatinib. J Surg Oncol 2011; 104: 901-906.

35 Cameron S, Schaefer IM, Schwoerer H, Ramadori G. Ten Years of Treatment with 400 mg Imatinib per Day in a Case of Advanced Gastrointestinal Stromal Tumor. Case Rep Oncol 2011; 4: 505-511.

36 Pappo AS, Janeway K, Laquaglia M, Kim SY. Special considerations in pediatric gastrointestinal tumors. J Surg Oncol 2011; 104: 928-932.

37 Pisters PW, Colomba C. Adjuvant imatinib therapy for gastrointestinal stromal tumors. J Surg Oncol 2011; 104: 896-900.

S-Editor: Gou SX | L-Editor: A | E-Editor: LJY